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Primary Care Treatment of HCV
in Medicaid Patients
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Mentors: Steven Lidofsky, MD, Charles MacLean,
MD, Scott Strenio, MD

§ As of 2010, there were 7,200 HCV+ people living in VT (1)
§ The 2014 reported mortality rate in VT for HCV was 5.2 per
every 100,000 persons (1)

§ Newly reported cases of HCV in VT have been increasing
as a result of the heroin epidemic (2)

Problem
Identification

§ HCV is a leading cause of cirrhosis, HCC, and liver
transplant (3)

§ With new, safer drug regimens, increased management of
HCV by primary care providers makes sense. However,
majority of patients still managed by specialists.

§ Since there is provider interest in treating HCV at CHCB,
how can we implement a model to treat HCV there?

§ Policy change in Dec 2016 increased coverage to Medicaid
patients with fibrosis scores of F2 or higher; requirement
for 6 mos drug & alcohol abstinence also removed (4)

§ In 2014 the total cost associated with chronic HCV was

Public Health
Cost

estimated at $6.5 billion and estimated to peak in 2024
at $9 billion (3)

§ Lifetime cost of an individual infected with HCV
estimated at $64,490 (3)

§ 2010-2011 Hospitalization rates for HCV related
problems increased 190% from 2004-2011 at an
estimated total cost of $3.5 billion (5)

Community
Perspective

§

What are some existing models for treatment of HCV in primary care settings and how
successful have those been? The ECHO program in New Mexico started about 20 years ago.
Essentially, primary care physicians in rural areas were trained by specialists to manage Hep C – all
they needed were some computers and webcams. One of the benefits to this is that once a week, all
the providers conference and present their patients. That gives you the benefit of seeing consults on
maybe 50-100 patients per week rather than just your own. This model was next adopted to WAMI
states, and now there are over 1,000 hubs across the US. It has expanded to treat multiple diseases,
including chronic pain and opiate addiction treatment. ECHO’s goal is to be reaching 1 billion
patients by the year 2020. In Vermont, no matter where you live you’re never more than an hour and
fifteen minutes from a major hospital, so there’s less of a travel barrier for seeing a specialist. The
reverse of this model, which has also been successful, is to send a specialist out into a rural area 1
day a week. So you could send a gastroenterologist out to an underserved community for one clinic
each week and schedule HCV patients then.

§

What barriers would you anticipate to setting up a treatment protocol for HCV in primary care
settings, and how might those barriers be overcome? If I wanted to start treating HCV patients at
CHBC tomorrow, my guess is that the greatest pushback would be from insurance or other
administrative barriers. The other question is, are there enough cases to stay up on the literature?
There are a couple of ways to address this. One is to have a close linkage to an expert (ie: a
gastroenterologist at UVM) who would be attending the major research meetings and keeping up
with trends in the field, and communicating that knowledge to primary care providers. Another is to
have HCV treatment be a niche area for one provider in the practice, and that person would keep up
with developments in the field and serve as a resource for the practice.

§

How could the success of a program like this be measured? You could create a patient registry
to collect data on treatment response, adverse effects, adherence to protocol, and monitoring, and
then compare that to metrics on patients at a medical center like UVMMC.

§

Do you have any suggestions in terms of prioritizing patients who haven’t yet been
screened?Looking back over the years, I’ve found that screening yield has decreased when testing
patients who always had normal LFTs. Looking at those trends can be a way to prioritize testing.

Charlie MacLean, MD
Professor of Medicine, General Internal
Medicine & Geriatrics
Department of Medicine
Associate Dean for Primary Care

§ There were some discrepancies in guidelines I reviewed regarding when to
order bi-annual ultrasounds to look for HCC versus an annual Fibroscan. sDo
you recommend ultrasounds at that interval for all patients being treated for
HCV, or only if there is a specific indication for it? HCC surveillance is generally
reserved for individual with known cirrhosis. Transient elastography is not a tool for
HCC evaluation, but it is used to evaluate the extent of hepatic fibrosis. There is no
consensus about its use in any surveillance program.

Community
Perspective
Steven Lidofsky, MD
Director of Hepatology, UVM

§ If our goal is to treat patients in-house at CHBC, how much and in what capacity
do you think GI would need to be involved? HCV treatment eligibility is determined
by health plans, and the landscape is shifting. I know that VT Medicaid demands HCV
management by subspecalists currently and restricts medication access based upon
hepatic fibrosis stage. This may all disappear within the next few years.

§ What thoughts do you have regarding invovlement of gastroenterologists in
primary care HCV treatment, and about having a provider here “subspecialize”
to a degree in HCV? The best reason to consider GI evaluation is to exclude the
presence of cirrhosis (since this requires specific management and beyond HCV
treatment). About 20-25% of patients with chronic HCV have cirrhosis, and the
question is how best to screen. One strategy is to send all HCV patients to GI for initial
evaluation prior to HCV treatment, and another is to use tools like the FIB-4 score to
avoid sending GI referrals when the probability of advanced hepatic fibrosis is low.
Having a knowledgeable in house HCV “expert” would be a plus to ensure high
quality HCV treatment.

§ What are the current DHVA pharmacy guidelines for

Community
Perspective
Scott Strenio, MD
CMO, Medicaid VT

HCV treatment? All patients require a prior authorization
for treatment, which is available online and spells out all
the different treatment regimens. In terms of the steps for
primary care, all you need is one consultation with a
specialist (either ID or GI) and evidence of fibrosis grade 2
or 3 – that can be established by any of the listed means,
including a Fibrosure. A Fibroscan is not necessary for
every patient.

§ How would you suggest primary care providers
collaborate with specialists to treat Medicaid patients?
I would recommend finding a specialist who is interested
in working with the clinic and supporting treatment in
primary care. A pharmacist is also a good resource.

§ Can you foresee any potential barriers to treating
CHCB patients? The medications are delivered, so if a
patient doesn’t have stable housing that could be a barrier.

§ 1 – Spoke with providers at CHCB to assess interest and
feasibility of treating HCV patients there, and to identify
barriers to doing so

§ 2 – Reviewed AASLD HCV treatment guidelines and

Intervention &
Methodology

guidelines presented to CHCB providers by local
gastroenterologists, and identified discrepancies

§ 3 – Clarified discrepancies in treatment guidelines and
questions regarding Medicaid coverage with UVM
physicians and CMO of Medicaid Vermont

§ 4 – Created a treatment algorithm for providers at
CHCB to determine when and how to treat Medicaid
patients with HCV.

Results

§ Learned that HCV treatment via primary care for VT
Medicaid patients is very feasible with current guidelines

§ Created treatment algorithm and resource sheet for CHCB
providers & presented at weekly provider meeting

§ The effectiveness of HCV treatment for Medicaid
patients through primary care could be evaluated by
establishing a patient panel at CHCB and tracking the
lab monitoring, medication adherence, treatment
response, and other pertinent variables. This could be
compared to similar data collected at UVMMC or other
centers where specialists treat HCV.

Evaluation

§ This algorithm can also be evaluated through
qualitative feedback from the providers utilizing it.

§ Limitations include time restriction that did not allow for
as much input from specialists in the development of
the algorithm as would be ideal, however it can be
updated in the future. It may also be that many patients
eligible for treatment are already being followed by
specialists and therefore are likely to be managed by
them.

§ In order to implement the use of the HCV treatment
algorithm, CHCB will need to identify specialists interested
in collaboratively managing patients with primary care.

§ Collaborating specialists can serve as a resource for
CHCB, regularly updating providers on new literature,
national meetings, etc.

Future
Recommendations

§ One or more providers at CHCB may also choose to adopt
HCV treatment as a niche area, and also stay abreast of
updates in the field to serve as an educational resource to
the practice.

§ Invite Dr. Scott Strenio of Medicaid for a meeting at CHCB
for any further clarification needed re: Medicaid
regulations, and to collaborate further on ideas for
expanding HCV treatment.
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